Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Laurus Labs gets no...

    Laurus Labs gets no USFDA observations for Vizag unit

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-14T10:00:13+05:30  |  Updated On 14 July 2019 10:00 AM IST
    Laurus Labs gets no USFDA observations for Vizag unit

    The maiden United States Food and Drug Administration (USFDA) audit for the unit was successfully completed without any observations and no Form 483 was issued, said Laurus Labs.


    New Delhi: Drug firm Laurus Labs Friday said audit of its unit 4 at Visakhapatnam in Andhra Pradesh by the US health regulator has been completed without any observations.


    Read Also: USFDA approves Glenmark Pharma anti-anginal drug Ranolazine ER Tablets


    "The inspection of unit 4 was carried out from July 8 - 12, 2019," Laurus Labs said in a filing to BSE.


    The maiden United States Food and Drug Administration (USFDA) audit for the unit was successfully completed without any observations and no Form 483 was issued, it added.


    Read Also: Sun Pharma Research Arm- SPARC gets USFDA orphan drug designation for novel kinase inhibitor


    As per the USFDA, Form 483 notifies the company's management of objectionable conditions.


    Laurus Labs is one of the Indian manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. The company also manufactures APIs in Oncology and other therapeutic areas.


    The company has also ventured into develop a Finished Dosages Forms on the back of existing strengths in APIs with a current capacity of 5 billion units per year, expandable up to 8 billion units per year. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses.


    Read Also: Solara Cuddalore facility successfully completes USFDA inspection

    AP unitBSEDrug firmLaurus LabsLaurus Labs unit 4Laurus Labs Visakhapatnampharmapharma companypharma newsUSFDAusfda auditVisakhapatnamVizag unit
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok